The Retatrutide clinical trials program has moved quickly from small proof-of-concept studies into large Phase 3 trials involving obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, cardiovascular disease, and long-term cardiometabolic outcomes.
If you have followed retatrutide mainly through weight-loss headlines, the clinical-trial record gives you a much clearer picture. Early studies asked whether the molecule could be administered safely and once weekly. Phase 2 tested dose-response relationships. Phase 3 is now asking whether those effects remain meaningful across larger and more clinically diverse populations.
For researchers following metabolic peptides, visit Research Peptides Canada for research-use-only compounds and available product information. This article focuses specifically on the progression and findings of retatrutide clinical trials, rather than repeating the compound’s general mechanism of action.
Why Is Retatrutide Being Studied in Clinical Trials?
Retatrutide, originally known as LY3437943, was designed as a single peptide that activates GIP, GLP-1, and glucagon receptors.
The scientific rationale was described by Coskun et al. in a 2022 Cell Metabolism paper. Preclinical experiments showed that the triple agonist reduced food intake and body weight while glucagon-receptor activity appeared to contribute an additional energy-expenditure component. Early pharmacokinetic work also suggested that the molecule could support once-weekly administration. (Coskun et al., 2022, Cell Metabolism)
But preclinical success does not establish clinical effectiveness.
Researchers therefore needed to answer several practical questions: Could repeated doses be tolerated in humans? What doses produced measurable metabolic effects? Would higher doses provide greater efficacy? Would the results hold in people with obesity, diabetes, and obesity-related complications?
Those questions shaped the development of retatrutide clinical trials from Phase 1 through Phase 3.
For more research-focused information, explore our Retatrutide research peptide and review the available product details.
What Did the Early Retatrutide Trials Tell Us?
One of the most important early human studies was the Phase 1b trial by Urva et al., published in The Lancet in 2022.
The randomized, double-blind study enrolled 72 adults with type 2 diabetes and evaluated once-weekly retatrutide for 12 weeks. Investigators tested ascending doses ranging from 0.5 mg through an escalation sequence reaching 12 mg.
The primary goal was not long-term weight reduction. It was to characterize safety and tolerability, while pharmacokinetics and pharmacodynamic effects were secondary objectives.
Researchers found that retatrutide had approximately a six-day half-life, supporting once-weekly dosing. At week 12, higher-dose groups showed significant placebo-adjusted reductions in average glucose and HbA1c. The highest escalation group also demonstrated a placebo-adjusted body-weight reduction of approximately 8.96 kg. Gastrointestinal disorders were the most frequently reported treatment-emergent adverse events. (Urva et al., 2022, The Lancet)
For the broader retatrutide clinical trials program, this was an important proof-of-concept result.
It suggested that the triple-agonist pharmacology seen in preclinical experiments could produce measurable metabolic changes in humans while also establishing a practical weekly dosing interval.
What Were the Most Important Findings From Phase 2?
Phase 2 moved the program into formal dose-response testing.
Type 2 Diabetes Trial
In 2023, Rosenstock et al. published a Phase 2 trial in The Lancet involving 281 adults with type 2 diabetes.
Participants received placebo, dulaglutide, or several retatrutide regimens ranging from 0.5 mg to 12 mg once weekly.
At 24 weeks, mean HbA1c changes reached -1.99% in one 8 mg escalation group and -2.02% in the 12 mg group, compared with -0.01% with placebo. At week 36, body-weight reduction was dose dependent, reaching approximately 16.8% with one 8 mg regimen and 16.9% with 12 mg. (Rosenstock et al., 2023, The Lancet)
The study also provided useful information about dose escalation. Gastrointestinal events occurred in 35% of retatrutide-treated participants overall and were more frequent in some higher or faster-escalation groups. Importantly, these Phase 2 findings directly informed dose selection for Phase 3.
Obesity Trial
The better-known Phase 2 obesity study was published by Jastreboff et al. in the New England Journal of Medicine in 2023.
The trial randomized 338 adults with obesity or overweight plus at least one weight-related condition.
At 48 weeks, average body-weight changes were:
| Weekly Retatrutide Dose | Mean Weight Change |
|---|---|
| 1 mg | -8.7% |
| 4 mg | -17.1% |
| 8 mg | -22.8% |
| 12 mg | -24.2% |
| Placebo | -2.1% |
At 12 mg, 83% of participants achieved at least 15% weight reduction, and 26% achieved at least 30%. Researchers also noted that the highest-dose groups had not clearly reached a weight-loss plateau by week 48. (Jastreboff et al., 2023, New England Journal of Medicine)
These Phase 2 retatrutide clinical trials established two major signals: efficacy increased with dose, but tolerability also became increasingly important.
For more research-focused information, explore our Retatrutide research peptide and review the available product details.
What Are Researchers Investigating in Phase 3?
By August 2026, Phase 3 research has expanded well beyond simple weight-loss measurement.
TRIUMPH-1: Obesity Without Diabetes
In May 2026, Lilly reported topline findings from TRIUMPH-1, a Phase 3 study that enrolled more than 2,300 participants with obesity or overweight without type 2 diabetes.
At 80 weeks, the efficacy estimand showed average weight reductions of:
- 19.0% with 4 mg
- 25.9% with 9 mg
- 28.3% with 12 mg
- 2.2% with placebo
Among those receiving 12 mg, 45.3% achieved at least 30% weight reduction. Participants with baseline BMI of at least 35 who continued into a 104-week extension reached an average reduction of 30.3% with 12 mg. (Eli Lilly, TRIUMPH-1, 2026)
Because these are company-reported topline findings, they should still be distinguished from full peer-reviewed publications.
TRANSCEND-T2D-1: Peer-Reviewed Phase 3 Diabetes Data
The strongest peer-reviewed Phase 3 evidence available so far comes from Bajaj et al., published in The Lancet in June 2026.
TRANSCEND-T2D-1 enrolled 537 adults with type 2 diabetes inadequately controlled through diet and exercise.
At 40 weeks, mean HbA1c changes were:
- -1.69% with 4 mg
- -1.86% with 9 mg
- -1.94% with 12 mg
- -0.81% with placebo
Mean body-weight changes were -11.5%, -13.9%, and -15.3% across the three retatrutide groups, compared with -2.6% with placebo. (Bajaj et al., 2026, The Lancet)
TRIUMPH-2 and TRIUMPH-3
In July 2026, Lilly reported two more pivotal results.
TRIUMPH-2 studied adults with obesity or overweight and type 2 diabetes. At 80 weeks, average weight reductions were 12.7% with 4 mg, 19.1% with 9 mg, and 20.8% with 12 mg, with HbA1c reductions reaching approximately 1.6 percentage points. (Eli Lilly, TRIUMPH-2, 2026)
TRIUMPH-3 studied people with severe obesity and established cardiovascular disease. Weight reduction reached 21.6% with 9 mg and 22.6% with 12 mg, versus 3.2% with placebo. However, cardiovascular-event numbers were too small to establish a definitive cardiovascular benefit. (Eli Lilly, TRIUMPH-3, 2026)
Obesity-Related Complications
Other Retatrutide clinical trials are testing whether weight change is accompanied by clinically meaningful improvements in obesity complications.
TRIUMPH-4 evaluated adults with obesity or overweight and knee osteoarthritis. Lilly reported average weight reduction of up to 28.7% at 68 weeks, alongside substantial reductions in WOMAC knee-pain scores. (Eli Lilly, TRIUMPH-4, 2025)
The Phase 3 program has also evaluated obstructive sleep apnea, while ongoing development includes cardiovascular and renal outcomes, metabolic liver disease, and other obesity-related conditions.
What Have Trials Reported About Dosing and Adverse Events?
The dosing information from retatrutide clinical trials should be understood as trial protocols, not personal-use guidance.
Earlier Phase 2 studies tested a wide range of maintenance doses and different starting-dose strategies. The NEJM obesity trial found that gastrointestinal adverse events were dose related and that beginning at 2 mg instead of 4 mg partially reduced these effects. (Jastreboff et al., 2023, NEJM)
Phase 3 trials subsequently adopted more structured escalation.
For example, TRIUMPH-2 participants began at 2 mg once weekly and increased every four weeks until reaching 4 mg, 9 mg, or 12 mg. The 12 mg sequence progressed through 2, 4, 6, and 9 mg before reaching the maintenance dose. TRIUMPH-3 used the same stepwise strategy for its 9 mg and 12 mg groups. (Eli Lilly, 2026)
Across trials, the most common adverse events have generally been gastrointestinal.
In the peer-reviewed TRANSCEND-T2D-1 trial, gastrointestinal events were predominantly mild to moderate and tended to subside over time. Discontinuation because of adverse events occurred in approximately 2–5% of retatrutide participants, and no severe hypoglycemia was reported. (Bajaj et al., 2026, The Lancet)
In TRIUMPH-2 and TRIUMPH-3, Lilly also reported dysesthesia in some participants. Adverse-event-related discontinuation reached 11.6% in the TRIUMPH-2 9 mg group and 13.5% in the TRIUMPH-3 12 mg group. (Eli Lilly, 2026)
For a broader overview of the compound, read our guide: Retatrutide Peptide: How It Works, What the Research Shows, and What We Know So Far
What Do the Clinical Trials Still Not Tell Us About Retatrutide?
The expanding retatrutide clinical trials program has answered many efficacy questions, but several important gaps remain.
First, strong weight reduction does not automatically prove fewer heart attacks, strokes, heart-failure events, or kidney outcomes.
TRIUMPH-3 included cardiovascular-event analyses, but event numbers were lower than anticipated and confidence intervals remained wide. Researchers therefore cannot yet conclude from that trial that retatrutide reduces major cardiovascular events. (Eli Lilly and Company)
Longer dedicated outcome trials will be much more informative.
Researchers also still need better answers about:
- durability of weight reduction over several years;
- outcomes after treatment withdrawal;
- long-term preservation of lean mass;
- rare adverse events;
- differences between responders and non-responders;
- long-term cardiovascular and renal outcomes;
- how well findings generalize across diverse populations.
The 2023 NEJM obesity trial itself noted limited racial and geographic diversity, since the study was U.S.-based and predominantly White. (Jastreboff et al., 2023, NEJM)
There is also a publication-quality distinction to keep in mind. TRANSCEND-T2D-1 has now undergone peer review, whereas several major TRIUMPH results remain topline company disclosures pending detailed journal publication.
That does not make the Phase 3 findings irrelevant. It simply means researchers should avoid treating every result as having the same evidentiary maturity.
As of August 2026, the overall trajectory of retatrutide clinical trials is increasingly clear: Phase 1 established practical pharmacokinetics and early metabolic activity, Phase 2 defined strong dose-response signals, and Phase 3 has begun confirming those effects across much larger and more complex patient populations.
For a broader explanation of the molecule itself, see our guide “Retatrutide Peptide: How It Works, What the Research Shows, and What We Know So Far.” For laboratory-focused peptide materials, visit Research Peptides Canada and review available research-use-only product information.
Disclaimer: The information and products discussed on this website are intended strictly for laboratory research and educational purposes only. They are not intended for human or veterinary use, diagnosis, treatment, prevention, or any form of clinical application.
4 Comments
This is a really useful overview of how the retatrutide research has progressed from early safety studies to much larger Phase 3 trials. I especially liked the distinction between peer-reviewed findings and company-reported topline results. Do you think the long-term cardiovascular and renal studies will have the biggest impact on how researchers evaluate retatrutide?
I found the Phase 2 results particularly interesting because the article shows how both efficacy and tolerability became important as the doses increased. The discussion about gastrointestinal adverse events also adds useful context to the trial results. I’d be interested to see whether longer follow-up changes the current understanding of the benefit-risk balance.
I really appreciate that this article doesn’t treat strong weight-loss results as proof that every long-term outcome has already been established. The section on unanswered questions, particularly durability after treatment withdrawal and preservation of lean mass, was very thought-provoking. These seem like important areas for future clinical research.